History

Clenbuterol is a substituted phenylaminoethanol (CAS 37148-27-9) developed as a long-acting beta-2 adrenergic agonist bronchodilator. It has never been approved by the FDA for human use under the FD&C Act, though some countries prescribe(d) it for bronchial asthma and airway obstruction (e.g., the brand Spiropent). In 1998 the FDA approved Ventipulmin (clenbuterol HCl) Syrup, a Boehringer Ingelheim prescription product for airway obstruction in horses; using clenbuterol as a livestock growth promoter is illegal in both the US and EU. Its long elimination half-life and beta-2-mediated "repartitioning" effects (more lean mass, less fat in animals) drove its adoption as an off-label fat-loss agent and, through contaminated meat, a cause of human poisoning outbreaks.

Clenbuterol is a potent, long-acting beta-2 adrenergic receptor agonist — a sympathomimetic bronchodilator used legitimately to treat airway obstruction in horses and, in some countries, asthma in people. It is widely misused off-label for fat loss and “lean-mass preservation.” It is important to be precise about what clenbuterol is and is not: it is not an anabolic-androgenic steroid, not an androgen-receptor agonist, not 17α-alkylated, and not a peptide. It has no esters (esterification is a steroid-formulation concept). The steroid-specific risks people sometimes assume — liver injury from 17α-alkylation, testosterone suppression, gynecomastia, virilization — do not apply to it. Its real dangers are cardiovascular and metabolic. This page is educational and harm-reduction oriented and contains no dosing, cycles, or sourcing information.

What it is

Clenbuterol (1-(4-amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol; CAS 37148-27-9) is a small-molecule, selective beta-2 adrenergic receptor agonist — a sympathomimetic, not a hormone and not a steroid. Its catecholamine-like backbone is resistant to the COMT/MAO enzymes that rapidly clear natural catecholamines, which gives it a long elimination half-life (roughly 25–39 hours) and prolonged effects.

Mechanistically, it binds and activates beta-2 adrenoceptors, coupling through the Gs protein to adenylyl cyclase and raising intracellular cyclic AMP. In airway and vascular smooth muscle this drives relaxation (bronchodilation). The “anabolic”/repartitioning effect seen prominently in animals — more lean mass, less fat — is mediated by beta-2 receptors on skeletal muscle and adipose tissue; the downstream pathway is not fully defined, but it is not androgen-receptor mediated. Oral absorption is high (~70–80%).

The claims

In bodybuilding, athletic, and “biohacking” circles, clenbuterol is promoted off-label for fat loss, body-fat reduction, and preservation of lean mass during a calorie deficit. It is especially popular among female users precisely because it lacks the androgenic/virilizing effects of anabolic steroids. In livestock it has been used illegally as a growth promoter to increase lean carcass yield — a use that is banned in the US and EU and has caused human poisonings through contaminated meat.

Its legitimate, evidence-backed uses are narrower: bronchodilation in equine airway obstruction (the FDA-approved veterinary indication), and asthma/airway obstruction in some countries that license it for human respiratory use.

What the evidence actually shows

The human muscle and strength evidence base is small, old, and rooted in clinical rehabilitation — not athletic-performance trials.

Orthopedic strength recovery (Maltin et al., 1993, Clin Sci (Lond) 84(6):651–654; PMID 8334811): a double-blind, randomized, placebo-controlled study in 20 healthy men recovering from open medial meniscectomy found clenbuterol associated with faster recovery of relative knee-extensor strength in the operated leg. The authors framed this as “therapeutic potential” for muscle-wasting conditions — a hypothesis-generating signal, not proof of performance enhancement.
Denervation atrophy (Jiang et al., 2011, Int Sch Res Notices/ISRN; PMID 22389867 / PMC3263717): a randomized, double-blind, placebo-controlled trial in 71 patients with brachial plexus injury found clenbuterol significantly mitigated loss of type I and type II muscle-fiber cross-sectional area over three months. Again, this is a specific clinical-atrophy setting, not healthy-athlete gains.

Most ergogenic claims are extrapolated from animal data, where clenbuterol robustly increases muscle mass and reduces fat (“repartitioning”). High-quality human RCTs showing meaningful strength, performance, or body-composition gains in healthy athletes are lacking. A broad review of WADA-prohibited substances (Heuberger & Cohen, Sports Medicine, 2018; PMC6422964) concluded that only a minority of prohibited classes have human evidence of genuine performance enhancement; its beta-2-agonist analysis focuses chiefly on inhaled agents (salbutamol/terbutaline) rather than clenbuterol specifically. Notably, the same animal models that show repartitioning also show clenbuterol can cause cardiac hypertrophy and myocyte necrosis, which tempers any enthusiasm.

Legal and regulatory status

US — never FDA-approved for humans. The FDA has never approved clenbuterol for human use under the FD&C Act. Human-use products are therefore unapproved, misbranded drugs; importing or selling clenbuterol for human use is illegal, and most US supply comes from illegal importation. The only legitimate availability is veterinary, by prescription — Ventipulmin (clenbuterol HCl) Syrup, approved 11 May 1998 for airway obstruction in horses. Using it as a livestock growth promoter is illegal in the US and EU.

Not a controlled substance. Clenbuterol is not scheduled under the federal Controlled Substances Act (per DEA Diversion Control). This is a key contrast with anabolic-androgenic steroids, which are Schedule III under the Anabolic Steroid Control Act of 1990 (effective 1991), expanded by the Anabolic Steroid Control Act of 2004 and the Designer Anabolic Steroid Control Act of 2014 (DASCA). Clenbuterol is not a steroid and does not fall under those statutes. (For further contrast, human growth hormone has its own dedicated criminal statute — distribution for non-approved human uses is prohibited under 21 U.S.C. § 333(e).)

Anti-doping (WADA 2026). Clenbuterol is explicitly named under category S1 ANABOLIC AGENTS, subsection S1.2 “Other Anabolic Agents,” alongside ractopamine, zilpaterol, zeranol, osilodrostat, and SARMs. S1 substances are prohibited at all times (in- and out-of-competition) and are non-Specified Substances. It sits in S1.2 (not S3, Beta-2 Agonists) because of its anabolic/repartitioning profile — unlike inhaled beta-2 agonists such as salbutamol and formoterol, which sit in S3 with inhaled-use thresholds and which clenbuterol does not get. (HGH and chorionic gonadotrophin fall under S2, also banned at all times.) There is no therapeutic threshold for clenbuterol; however, WADA’s Stakeholder Notice on meat contamination provides that a finding at or below 5 ng/mL is reported as an Atypical Finding and investigated for possible contaminated-meat origin before being pursued as an Adverse Analytical Finding, reflecting that low-level positives can arise from contaminated meat in certain regions.

Safety

Clenbuterol’s adverse profile is driven by beta-adrenergic overstimulation, made worse by its long half-life — overdose symptoms can persist for many hours.

Cardiovascular (the main danger): tachycardia, palpitations, and arrhythmias (including supraventricular tachycardia and reported atrial fibrillation), hypertension or reflex hypotension, chest pain, and myocardial injury. Overdose/poisoning case reports describe tachyarrhythmia, hypokalemia, hyperglycemia, lactic acidosis, and elevated cardiac biomarkers; management can require hospitalization, beta-blockade, and potassium repletion. Animal studies show clenbuterol-induced cardiac hypertrophy and myocyte necrosis.
Metabolic / electrolyte: beta-2 stimulation shifts potassium into cells, producing hypokalemia (an arrhythmia risk), along with hyperglycemia and lactic acidosis.
Neuromuscular / CNS: skeletal-muscle tremor, nervousness/anxiety, headache, insomnia, dizziness, and sweating; nausea and vomiting in poisoning.
Contaminated-meat poisonings: eating clenbuterol-contaminated meat or liver (from illegal livestock use) has caused documented human outbreaks — Spain (1990, roughly 135 cases from veal liver), China (Shanghai 2006, around 336 hospitalized; Guangdong 2009), and Italy. Symptom onset is typically about 0.5–6 hours, resolving over roughly 2–6 days.
What does NOT apply to clenbuterol: hepatotoxicity from 17α-alkylation, HPTA suppression and infertility, gynecomastia, virilization, and polycythemia/elevated hematocrit are anabolic-steroid effects, not clenbuterol effects. Clenbuterol does not act on androgen receptors or the HPG axis and is not 17-alkylated, so it does not cause these. (Its appeal to female users is precisely the absence of virilization.) Those toxicities belong to anabolic steroids.

Bottom line

Clenbuterol is a long-acting beta-2 agonist, not a steroid and not a peptide. The human evidence for its muscle-preserving effects is limited to small, old clinical-rehabilitation trials (post-surgical and denervation atrophy), and the more dramatic fat-loss/lean-mass claims rest largely on animal data — there are no rigorous RCTs showing it benefits healthy athletes. It has never been FDA-approved for human use (it is a veterinary-only prescription drug in the US), it is not a controlled substance, and it is banned in sport at all times as an anabolic agent under WADA S1.2. Its real risks are cardiovascular and metabolic — arrhythmia, hypokalemia, and documented poisonings — amplified by its long half-life.

Evidence grade: Preliminary human.